Featured Research

from universities, journals, and other organizations

Study finds one treatment stands above others for adults with Langerhans cell histiocytosis

Date:
August 15, 2012
Source:
Baylor College of Medicine
Summary:
A physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis in bones.

A study by a Baylor College of Medicine physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis in bones. LCH is a disease that can affect the skin, mouth, ears, bones, brain, gastrointestinal system, liver, spleen, or bone marrow.

In the study, appearing in the current issue of PLoS ONE, researchers reviewed health records for 58 adults with the disease and compared the effectiveness of three chemotherapy treatments vinblastine/prednisone, 2-Chlorodeoxyadenosine, and cytosine arabinoside.

"Cytarabine (cytosine arabinoside) is clearly the winner here ­it's the most effective and least toxic," said Dr. Ken McClain, professor of pediatrics ­hematology/oncology at BCM and director of the Histiocytosis Program at Texas Children's Cancer Center.

Little research

The study is important because LCH is rare in adults and there is very little research on the disease. There have been no studies in the literature up to now that compare different treatments, according to McClain.

"The number one thing that I hope comes out of this study is that physicians stop using vinblastine/prednisone, which is the least effective and most toxic chemotherapy treatment for this disease," he said.

Rare disease

LCH occurs when white blood cells called histiocytes and lymphocytes gather together and attack the skin, bones, brain, gastrointestinal system, major organs, mouth and ears. It affects children and adults and can range from a single skin lesion to multi-organ involvement. It can be chronic and debilitating and, in some cases, fatal.

The study reviewed patients who were seen from 2001 to 2011 at BCM. It offers data that could be useful for future clinical trials but, more importantly, it provides literature for physicians who do not know how to treat patients with this rare disease.


Story Source:

The above story is based on materials provided by Baylor College of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Baylor College of Medicine. "Study finds one treatment stands above others for adults with Langerhans cell histiocytosis." ScienceDaily. ScienceDaily, 15 August 2012. <www.sciencedaily.com/releases/2012/08/120815174852.htm>.
Baylor College of Medicine. (2012, August 15). Study finds one treatment stands above others for adults with Langerhans cell histiocytosis. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/08/120815174852.htm
Baylor College of Medicine. "Study finds one treatment stands above others for adults with Langerhans cell histiocytosis." ScienceDaily. www.sciencedaily.com/releases/2012/08/120815174852.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins